DOCSLIB.ORG

FIRM Directory of Cell and Gene Therapies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FIRM Directory of Cell and Gene Therapies FIRM directory of cell and gene therapies As part of the BIA’s Memorandum of Understanding with the Forum for Innovative Regenerative Medicine (FIRM), the BIA is hosting a directory of FIRM companies who are operating in the cell and gene therapy area. The directory has been sorted into nine sections. • Categories - page 2 • Equipment and Devices - Page 4 • Cell Tissue supply - Page 5 • Regenerative medicine products - Page 6 • Contract service - Page 7 • Chemicals Material - Page 10 • Pharmaceutical company - Page 11 • Facilities Construction - Page 12 • Logistics support - Page 13 • Other services - Page 14 About FIRM Here at FIRM, our objective is to establish systems to ensure that the community has safe and stable access to the benefits of research into regenerative medicine. Not only do we seek complete cures for the ills that many medical patients suffer from, but we also strive to safeguard the national interest, contribute to international society, and pave the way for the commercialization of new regenerative medicine techniques with the purpose of building a social consensus on the application of such techniques. To that end, we engage in the following activities: • Advice from an international standpoint on commercialization strategies and issues regarding regenerative medicine; • Exchanges and tie-ups in Japan and internationally related to regenerative medicine; • Regenerative medicine surveys, publication of results and statistics; • Hosting and organizing research workshops and open lectures on regenerative medicine; • All activities incidental or related to the foregoing. 1 | P a g e Categories Category Business Equipment and devices (reusable/capital) Manufacture and sales of reusable (capital) manufacturing equipment Manufacture and sales of reusable (capital) research equipment Manufacture and sales of analytical and testing equipment Manufacture and sales of tissue collection and handling equipment Other Cell/Tissue supply Materials for pre-clinical study Materials for clinical study Regenerative medicine products Tissue engineering Cell therapy Gene and gene modified cell therapy Immunotherapy Other Contract service CMO (Contract manufacturing service under GMP grade (CPC) for clinical study CMO (Contract manufacturing service under GMP grade (CPC) for commercialization CRO (Contract preclinical study) CRO (Contract research and development) CRO (Contract clinical trial) Cell Banking Other Chemicals/Materials Reagent/Medium (clinical and preclinical) Test (kit/reagent) Disposable research equipment (research grade plastic dish, etc.) Disposable production equipment (GMP grade plastic dish, etc.) Other Pharmaceutical company Pharmaceutical company Facilities/Construction CPC construction 2 | P a g e Air conditioning Other Shipping/transport Logistics/Support Coldchain Tracking/monitoring Decision support tools and software Logistics/co-ordination Other Other services Human resource training/dispatch Consulting-R&D Consulting - regulatory Consulting - CMC/analytical Consulting - Patent attorney Consulting - financial serivces Consulting - other Patent attorney/lawyer/accountant etc Finance/Insurance Venture capital Other 3 | P a g e Equipment and Devices Manufacture Manufacture Manufacture Manufacture and sales of and sales of and sales of and sales of reusable reusable tissue Company/organisation analytical Other Website Contact details (capital) (capital) collection and testing manufacturing research and handling equipment equipment equipment equipment CellSeed Inc. 〇 http://www.cellseed.com/index-e.html Cyfuse Biomedical K.K. 〇 〇 https://www.cyfusebio.com/en/ Hitachi, Ltd. 〇 〇 http://www.hitachi.com/ INABATA&CO.,LTD. 〇 〇 https://www.inabata.co.jp/english/ KANEKA CORPORATION 〇 http://www.kaneka.co.jp/kaneka-e/ Kawasaki Heavy Industries, 〇 〇 〇 http://global.kawasaki.com/en/index.html Ltd. Merck Ltd. 〇 〇 https://www.merckgroup.com/en 〇 Sales of MICRON Inc. Medical image https://firm.or.jp/en analysis software NICHIREI BIOSCIENCES 〇 https://www.nichirei.co.jp/bio/english/index.html INC. Nissan Chemical Corporation 〇 https://www.nissanchem.co.jp/eng/ NSK Ltd. 〇 〇 Olympus Corporation 〇 https://www.olympus-global.com/ PHC Corporation 〇 https://www.phchd.com/global/ SANKI Engineering Co., Ltd 〇 https://www.sanki.co.jp/en/ SCREEN Holdings Co., Ltd. 〇 〇 https://www.screen.co.jp/eng/index.html SYSMEX CORPORATION 〇 〇 〇 http://www.sysmex.co.jp/en/index.html TERUMO CORPORATION 〇 http://www.terumo.com/ ZIMMER BIOMET 〇 https://firm.or.jp/en 4 | P a g e Cell Tissue supply Materials for Materials for Company/organisation pre-clinical Website Contact details Comments clinical study study Cyfuse Biomedical K.K. 〇 https://www.cyfusebio.com/en/ FUJIFILM Corporation 〇 〇 http://www.fujifilm.com/ KANEKA 〇 〇 http://www.kaneka.co.jp/kaneka- CORPORATION e/ TAKARA BIO INC. 〇 http://www.takara-bio.com/ 5 | P a g e Regenerative medicine products Gene and gene Tissue Company/organisation Cell therapy modified cell Immunotherapy Other Website Comments engineering therapy Asahi Kasei Corporation 〇 http://www.asahi-kasei.co.jp/asahi/en/ Astellas Pharma Inc. 〇 〇 https://www.astellas.com/en/ BrightPath Biotherapeutics Co., 〇 〇 〇 https://www.brightpathbio.com/english/index.html Ltd. CellSeed Inc. 〇 〇 http://www.cellseed.com/index-e.html Cyfuse Biomedical K.K. 〇 〇 https://www.cyfusebio.com/en/ Daiichi Sankyo Co., Ltd. 〇 〇 https://www.daiichisankyo.com/ Evonik Japan Co., Ltd. 〇 https://corporate.evonik.com/en/Pages/default.aspx FUJIFILM Corporation 〇 〇 〇 http://www.fujifilm.com/ FUJISOFT Tissue Engineering 〇 〇 http://www.fstec.co.jp/en/ Co., Ltd. HEALIOS K.K. 〇 http://www.healios.co.jp/ Japan Tissue Engineering Co., 〇 http://www.jpte.co.jp/english/index.html Ltd. JCR Pharmaceuticals Co., Ltd. 〇 http://www.jcrpharm.co.jp/en/site/en/index.html KANEKA CORPORATION 〇 http://www.kaneka.co.jp/kaneka-e/ LYMPHOTEC Inc. 〇 http://www.lymphotec.co.jp/english/ Planning Clinical Trial on Knee Cartilage licensed by Histgenics in US MEDINET Co., Ltd. 〇 〇 https://www.medinet-inc.co.jp/english/ Planning Clinical Trial on DC Therapy for ATL cooperating with Kyushu Cancer Center Metcela Inc. 〇 〇 https://www.metcela.com/en/ Novartis Pharma K.K. 〇 https://www.novartis.co.uk/ Otsuka Pharmaceutical Factory, 〇 https://www.otsukakj.jp/en/ Inc. ROHTO Pharmaceutical Co., Ltd. 〇 https://www.rohto.co.jp/global/ Sumitomo Dainippon Pharma 〇 https://www.ds-pharma.com/ Co., Ltd. 〇 TAKARA BIO INC. 〇 http://www.takara-bio.com/ oncolytic virus Takeda Pharmaceutical Company 〇 〇 https://www.takeda.com/ Limited Teijin Limited 〇 〇 〇 https://www.teijin.com/ TERUMO CORPORATION 〇 http://www.terumo.com/ 6 | P a g e Contract service CMO CMO (Contract (Contract manufacturing CRO manufacturin CRO CRO service under (Contract Cell Company/organisatio g service (Contract (Contrac GMP grade research and Bankin Other Website Comments n under GMP preclinica t clinical (CPC) for development g grade (CPC) l study) trial) commercializatio ) for clinical n study A2 Healthcare ○ http://www.a2healthcare.com/en/ Corporation ○ manufacture and development of API Co.,Ltd. biopharmaceutica http://www.api3838.co.jp/en/index.html l drugs, diagnostic drugs and reagent CellSeed Inc. ○ ○ http://www.cellseed.com/index-e.html CMIC Co., Ltd. ○ ○ ○ ○ ○ ○ https://www.cmicgroup.com/e/ Cyfuse Biomedical ○ https://www.cyfusebio.com/en/ K.K. Evonik Japan Co., ○ ○ https://corporate.evonik.com/en/Pages/default.asp Ltd. x FUJISOFT Tissue ○ ○ ○ ○ ○ http://www.fstec.co.jp/en/ Engineering Co., Ltd. iPS PORTAL, Inc. ○ http://ipsportal.com/en/ IQVIA Services Japan ○ https://www.iqvia.com/ K.K. Japan Tissue ○ ○ ○ ○ ○ http://www.jpte.co.jp/english/index.html Engineering Co., Ltd. KANEKA ○ ○ http://www.kaneka.co.jp/kaneka-e/ CORPORATION LYMPHOTEC Inc. ○ ○ http://www.lymphotec.co.jp/english/ For Immuno cell therapy MEDINET Co., Ltd. ○ 〇 https://www.medinet-inc.co.jp/english/ For other type of cells, other than immuno cells ○ Analysis and MICRON Inc. ○ http://micron-kobe.com/english/ interpretation of medical images 7 | P a g e Nikon CeLL ○ ○ ○ http://www.ave.nikon.co.jp/ncli/en/ innovation Co. Ltd. ○ PAREXEL In country ○ https://www.parexel.com/ International Inc. Clinical Care- taker POC Clinical ○ ○ ○ https://www.poccr.com/en/ Research Inc. ROHTO Pharmaceutical Co., ○ https://www.rohto.co.jp/global/ Ltd. SYSMEX ○ http://www.sysmex.co.jp/en/index.html CORPORATION ○ TAKARA BIO INC. ○ ○ ○ ○ ○ viral vector http://www.takara-bio.com/ production 8 | P a g e Chemicals Materials Disposabl Disposabl e e research production Reagent/Mediu Test equipment equipment Company/organisation m (clinical and (kit/reagent (research Other Website Contact details (GMP preclinical) ) grade grade plastic plastic dish, etc.) dish, etc.) AJINOMOTO CO., INC. 〇 https://www.ajinomoto.com/en/ API Co.,Ltd. 〇 http://www.api3838.co.jp/en/index.html https://firm.or.jp/e Cell Science & Technology Institute Inc. 〇 n CellSeed Inc. 〇 〇 http://www.cellseed.com/index-e.html Dai Nippon Printing Co., Ltd. 〇 〇 http://www.dnp.co.jp/eng/ Dojindo Laboratories 〇 https://www.dojindo.com/ Evonik Japan Co., Ltd. 〇 https://corporate.evonik.com/en/Pages/default.aspx FUJIFILM Corporation 〇 〇 http://www.fujifilm.com/ FUJIFILM Wako Pure Chemical Corporation 〇 〇 http://ffwk.fujifilm.co.jp/en/index.html INABATA&CO.,LTD. 〇 〇 〇 〇 〇 https://www.inabata.co.jp/english/ JAPAN BIOMEDICAL CO., LTD. 〇 https://www.japan-biomedical.jp/ KANEKA CORPORATION 〇 http://www.kaneka.co.jp/kaneka-e/ KANTO CHEMICAL CO., INC. 〇 〇 https://www.kanto.co.jp/english/index.html KOKEN CO., LTD. 〇 〇 https://atelocollagen.com/en/
Load more

Recommended publications
  • Brochure Vermed Endotube
    ORDER INFORMATION 4011404C Disposable Tubing - OLYMPUS GI Endoscopes 4011405C Disposable Tubing - PENTAX GI Endoscopes PROVIDING A TAILORED SOLUTION 4011406C Disposable Tubing - FUJIFILM GI Endoscopes 500-600 Series A TAILORED SOLUTION... 4011407C Disposable Tubing - FUJIFILM GI Endoscopes 700 Series for endoscopic irrigation and insuation tubing FUNCTIONALITY – Designed for Optimal Performance 4011409C Disposable Tubing + CO Option - OLYMPUS GI Endoscopes 4011410C Disposable Tubing + CO Option - PENTAX GI Endoscopes 4011411C Disposable Tubing + CO Option - FUJIFILM GI Endoscopes 500-600 Series 4011412C Disposable Tubing + CO Option - FUJIFILM GI Endoscopes 700 Series EFFICIENCY – Enables Efficient Running of the Endoscopic Suite INFECTION CONTROL – Minimises Infection Risk to Improve Patient Outcomes 4011413C CO Insufflation Tubing with Hydrophobic Filter - LUER Connection 4011414C CO Insufflation Tubing with Hydrophobic Filter - ADAPTER Connection 4011415C Connection Adapter for Insufflator OLYMPUS UCR COMPATIBILITY – Comprehensive Range to Simplify Procurement & Stock Management 4011416C Connection Adapter for Insufflator FUJIFILM GW-1 4011417C Connection Adapter for Insufflator FUJIFILM GW-100 The ENDOtube range can cover your lower GI endoscopic irrigation and insuation tubing requirements and meet your needs. 4011418C Disposable Irrigation Tubing - EMED Pump / OLYMPUS GI Endoscopes 4011419C Disposable Irrigation Tubing - OLYMPUS Pump / OLYMPUS GI Endoscopes 4011420C Disposable Irrigation Tubing - ENDOGATOR Pump / OLYMPUS GI Endoscopes LARGE
    [Show full text]
  • Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles
    Foreign Agricultural Service GAIN Report Global Agriculture Information Network Approved by: Date: 07/23/99 Sarah D. Hanson GAIN Report #JA9087 U.S. Embassy Market Brief - Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles This report was prepared by the USDA’s Foreign Agricultural Service for U.S. exporters of food and agricultural products. This information is in the public domain and may be reprinted without permission. Use of commercial or trade names does not imply approval nor constitute endorsement by USDA/FAS. Tokyo[JA1], JA GAIN Report #JA9087 Page 1 of 24 Company Name Amway Japan Product Sector(s) Health and Functional Food Address 1-8-1, Shimo-Meguro Number Of Employees 728 Meguro-ku, Tokyo 153-8686 Number of Factories Overseas Contact Phone Number 03-5434-8484 Fax Number 03-5434-4923 Email Web Page Address www.amway.co.jp/amway_japan/ Contact Person Masura Iwata Executive Driector, External Affairs and Public Relations Sales and Net Profits Main Suppliers Year Sales (Mil. \) Net Profits 1995 177,991 22,424 1996 212,195 25,130 1997 203,361 26,638 Key Products % of Total Company Profile and Strategies Home Care Products 9 Japanese corporation of nonstore sales operator Amway (US). Housewares 30 Registered sales personnel involved in direct sales of detergents, Personal Care 34 cosmetics, kitchenware and nutritional supplements. Nutritional Supplements 23 Others 4 Main Brands Triple X (vitamin and mineral supplement), Nutri Protein, Acerola C (vitamin supplement), Salmon-Omega 3, Hon-E-Cece, Ironics, Beta Carotene A, Wheat Germ E. Main Ingredients Vitamins, protein concentrates, iron concentrates, calcium concentrates, beta caroten, wheat germ.
    [Show full text]
  • ANNUAL REPORT FY2014 for the Year Ended March 31, 2015 Courtesy of Mizushima LNG Co., Ltd
    ANNUAL REPORT FY2014 For the year ended March 31, 2015 Courtesy of Mizushima LNG Co., Ltd. Financial Highlights Years Ended March 31, 2015, 2014, 2013, 2012, and 2011 2015 2014 2013 2012 2011 For the Year (Millions of Yen) Revenues ¥480,979 ¥446,147 ¥398,918 ¥254,675 ¥247,082 Cost of revenue 435,327 404,685 356,402 215,783 215,563 Operating income 21,466 21,079 25,113 24,197 17,544 Income before income taxes and minority interests 22,012 22,538 26,747 23,543 11,476 Net income 11,029 13,447 16,077 14,364 7,979 At Year-End (Millions of Yen) Total assets ¥515,839 ¥475,288 ¥435,379 ¥365,795 ¥353,392 Profile Total equity 208,405 198,031 189,356 168,737 155,758 Current ratio (%) 151.0 156.3 166.3 165.5 173.8 Founded in 1948 in the post war period to reconstruct Japan, Chiyoda started its engi- Per Common Share (Yen) neering business for domestic projects mainly in petroleum refining, gas processing and Earnings per share (EPS) ¥42.58 ¥51.91 ¥62.06 ¥55.44 ¥30.79 petrochemical fields, and expanded into overseas projects in the 1960s. Since then, Chiyoda Book value per share (BPS) 796.89 758.31 727.24 648.95 599.15 has been and is growing steadily under the corporate philosophy of enhancing its business by aiming for harmony between energy and the environment and contributing to the Dividend per share 13.0 16.0 19.0 17.0 11.0 sustainable development of society.
    [Show full text]
  • FTSE Japan ESG Low Carbon Select
    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
    [Show full text]
  • Olympus Corporate Social Responsibility Report Digest
    Olympus Corporate Social Responsibility Report Digest Toward the Realization of a Better Livelihood and Happiness To protect the environment, this report was printed on FSC-certified paper produced using resources from appropriately managed forests, soy ink and waterless printing technology. It has received third-party approval from the Color Universal Design Organization, a nonprofit organization in Japan, as being suitable for people with a wide range of color-vision characteristics. Olympus Corporation Contact CSR Department, CSR Division Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0914, Japan TEL:+81-3-6901-9299 FAX:+81-42-642-9017 E-mail:[email protected] Issued in August 2010 (previous edition issued in August 2009) Olympus Corporate Social Responsibilities Activities website http://www.olympus-global.com/en/corc/csr/ Circulation: 4,000 copies Next volume scheduled for issue in August 2011 X020-10E①1008T Printed in Japan Introduction The Olympus Group began to publish its “Environmental Report” in 2000. In 2005 the report was expanded to include information concerning corporate governance and the social aspects of the Group’s activities, and the title was changed to the “Corporate Social Responsibility Report”. Since 2008, the booklet has taken the form of a digest of the information provided on the Olympus Group CSR website. It is designed to provide a clear overview of the corporate activities of the Olympus Group, together with information about policies, initiatives and significant events in the current business year. Overview of Corporate Social Responsibility Information This Report and the Olympus CSR website The notation WEB WEB indicates that more detailed Olympus information is available on our website.
    [Show full text]
  • Mizuho BK Custody and Proxy Board Lot Size List OCT 27, 2020 21LADY
    Mizuho BK Custody and Proxy Board Lot Size List OCT 27, 2020 Board Lot Stock Name (in Alphabetical Order) ＩＳＩＮ Code ＱＵＩＣＫ Code Size 21LADY CO.,LTD. 100 JP3560550000 3346 3-D MATRIX,LTD. 100 JP3410730000 7777 4CS HOLDINGS CO.,LTD. 100 JP3163300001 3726 A DOT CO.,LTD 100 JP3160590000 7063 A-ONE SEIMITSU INC. 100 JP3160660001 6156 A.D.WORKS GROUP CO.,LTD. 100 JP3160560003 2982 A&A MATERIAL CORPORATION 100 JP3119800005 5391 A&D COMPANY,LIMITED 100 JP3160130005 7745 A&T CORPORATION 100 JP3160680009 6722 ABALANCE CORPORATION 100 JP3969530009 3856 ABC-MART,INC. 100 JP3152740001 2670 ABHOTEL CO.,LTD. 100 JP3160610006 6565 ABIST CO.,LTD. 100 JP3122480001 6087 ACCESS CO.,LTD. 100 JP3108060009 4813 ACCESS GROUP HOLDINGS CO.,LTD. 100 JP3108190004 7042 ACCRETE INC. 100 JP3108180005 4395 ACHILLES CORPORATION 100 JP3108000005 5142 ACMOS INC. 100 JP3108100003 6888 ACOM CO.,LTD. 100 JP3108600002 8572 ACRODEA,INC. 100 JP3108120001 3823 ACTCALL INC. 100 JP3108140009 6064 ACTIVIA PROPERTIES INC. 1 JP3047490002 3279 AD-SOL NISSIN CORPORATION 100 JP3122030004 3837 ADASTRIA CO.,LTD. 100 JP3856000009 2685 ADEKA CORPORATION 100 JP3114800000 4401 ADISH CO.,LTD. 100 JP3121500007 7093 ADJUVANT COSME JAPAN CO.,LTD. 100 JP3119620007 4929 ADTEC PLASMA TECHNOLOGY CO.,LTD. 100 JP3122010006 6668 ADVAN CO.,LTD. 100 JP3121950004 7463 ADVANCE CREATE CO.,LTD. 100 JP3122100005 8798 ADVANCE RESIDENCE INVESTMENT CORPORATION 1 JP3047160001 3269 ADVANCED MEDIA,INC. 100 JP3122150000 3773 ADVANEX INC. 100 JP3213400009 5998 ADVANTAGE RISK MANAGEMENT CO.,LTD. 100 JP3122410008 8769 ADVANTEST CORPORATION 100 JP3122400009 6857 ADVENTURE,INC. 100 JP3122380003 6030 ADWAYS INC. 100 JP3121970002 2489 AEON CO.,LTD. 100 JP3388200002 8267 AEON DELIGHT CO.,LTD.
    [Show full text]
  • “Mirai Engineering” a Grand Opportunity for the Future
    “MIRAI ENGINEERING” A GRAND OPPORTUNITY FOR THE FUTURE ANNUAL REPORT FY2016 For the year ended March 31, 2017 CHIYODA CORPORATION ANNUAL REPORT FY2016 PROFILE Chiyoda Corporation is a leading integrated engineering and construction company with a signifi cant INDEX presence in the global oil and gas market, and customers in more than 60 countries. Especially in the fi eld 02 Profile 19 Topics 39 Risk Management of LNG plant engineering and construction, we are a global leader, with a track record of undertaking 03 At a Glance 21 Chiyoda’s ESG Initiatives 41 Corporate Information projects that account for around 40% of the world’s total LNG plant capacity. 05 To Our Shareholders 31 Corporate Governance 43 Stock Information Established in 1948, Chiyoda started with domestic projects in petroleum refining, petrochemicals 11 Financial Highlights 35 Directors & Officers and gas processing. Since the 1970s, Chiyoda has developed a powerful global footprint, taking 13 Business Overview 37 Corporate Governance Dialogue advantage of the many opportunities in the engineering, procurement and construction of energy- related plants, while building a first-class reputation for technological capability, safety and reliability. 2017 During its 70-year history, the Chiyoda Group has been growing steadily under the corporate Order awarded for the pilot plant for production of renewable jet and diesel philosophy of enhancing business by aiming for harmony between energy and the environment, while fuels for euglena Co., Ltd. in Japan contributing to the sustainable development of society. In addition, Chiyoda has expanded business 2003 Order awarded for Sakhalin ll LNG Project into the offshore and upstream sectors, new energy and renewable energies.
    [Show full text]
  • Tokyo Food Technology Week 2021
    Exhibit Brochure Tokyo Food Technology Week 2021 Sep. 2-3 2021 Sep. 2-3 2021 10:00～17:00 PACIFICO YOKOHAMA Exhibition Hall C [Website] https://tokyofoodtechnology.com/2021/en.pdf Organizer：EJK Japan, Ltd./ The Japan Food News Show profile The Gateway into Japan Market ! Tokyo Food Technology Week “Tokyo Food Technology Week” will be expandingly held by including “P & B JAPAN”, “Nutritious Food Ingredients EXPO”, and “food ingredients EXPO for Pre-packaged, Frozen, and Instant food”. TFTW creates the synergistic effect of 3 shows by proposing the cutting- edge technology that shows new trends in the whole food industry. LOGO nd NAME OF 2 Nutritious Food 1st food ingredients EXPO for Pre- 9th P&B JAPAN (P&B) SHOW Ingredients EXPO (NFI) packaged, Frozen, and Instant food (PFI) ORGANIZER(S) EJK Japan, Ltd. EJK Japan, Ltd./ The Japan Food News Food ingredients for bread Health functional food Food Ingredients (meat, & confectionery (flour, oil, ingredients (vitamin & sea food, vegetable, fruit, yeast, jam, honey, frozen mineral, oligo sugar, food cereal, seasoning, spice, dough, etc. ) / Food fiber, lactic acid bacteria, herb etc.) / Food additives ingredients for sandwich, sugar alcohol, protein, / Professional products for EXHBITOR burger (meat, vegetable, amino acid, enzyme, etc.) restaurant chain / Food PROFILE dairy product, sauce, etc. ) Vegetable / Herb / Honey processing technology / Coffee & tea & beverages product / Soy product / (freezing, thawing, / Kitchen equipment / POS Component analysis / sterilizer drying etc. )/ register
    [Show full text]
  • ANNUAL REPORT 2000 Fiscal Year Ended March 31, 2000
    Engineering a Better Tomorrow ANNUAL REPORT 2000 Fiscal Year Ended March 31, 2000 CHIYODA CORPORATION c1 CONTENTS 1 Profile 2 A Message from the Management 4 Review of Operations 4 Hydrocarbon Sector 6 Non-Hydrocarbon Sector 8 Main Projects 10 Financial Section 30 Corporate Directory 31 Board of Directors 31 Corporate Data c2 PROFILE Since its founding in 1948, Chiyoda Corporation has earned a strong reputation as a global engineering company with roots in the hydrocarbon processing industry. Leveraging its vast accumulated experience, Chiyoda has set its sights on becoming an integrated provider of engineering and construction services to customers around the world. The Company is now applying its technological and engineering expertise to the development of such areas as environmental systems, nonferrous metal processing, pharmaceutical manufacturing, food processing, factory automation, automotive plants, theme parks, and aerospace development. To better serve globally competi- tive markets, Chiyoda believes in continuous renewal to realize its mission of becoming the engineering company of choice for customers worldwide. Ethylene Plantį (800,000 t/y) Ethylene Glycolį Plant (450,000 t/y) LNG Plantį (3,300,000 t/y x 2) Exxon Chemical Singapore Private Ltd. Eastern Petrochemical Company (SHARQ) Oman LNG L.L.C. (Chawan, Jurong Island, Singapore) (Al-Jubail, The Kingdom of Saudi Arabia) (Qalhat, Sultanate of Oman) CHIYODA CORPORATION 1 1 A MESSAGE FROM THE MANAGEMENT Domestic orders continued to be firm overall and totaled ¥53 billion, with impressive results from the chemical, pharmaceutical, and energy sectors. Regrettably, new international hydrocarbon- related orders fell short of expectations, and Chiyoda was only able to book orders worth ¥27 billion.
    [Show full text]
  • Albuminuria, Expression of Nicotinamide Adenine Dinucleotide
    991 Hypertens Res Vol.30 (2007) No.10 p.991-998 Original Article Albuminuria, Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Monocyte Chemoattractant Protein-1 in the Renal Tubules of Hypertensive Dahl Salt-Sensitive Rats Shigemoto FUJII1), Ling ZHANG1), and Hiroaki KOSAKA1) In chronic renal diseases, experimental and human data suggest that excess albumin filtered through the glomerular capillary barrier is over-reabsorbed by proximal tubular cells, thereby activating these cells and upregulating the expression of chemokines. On the other hand, a high-salt diet has been shown to induce proteinuria in hypertensive Dahl salt-sensitive (DSS) rats, accompanied with the expression of reduced nic- otinamide adenine dinucleotide phosphate (NADPH) oxidase in the kidney. In the current study, we therefore examined albuminuria and the expressions of NADPH oxidase and monocyte chemoattractant protein-1 (MCP-1) in the renal tubular cells in hypertensive DSS rats, as well as the effects of the antioxidant N-ace- tylcysteine (NAC) on each of these parameters. DSS rats were fed a normal-salt diet (0.24% NaCl), a high- salt diet (8% NaCl), or a high-salt diet plus NAC supplementation (15 mg/mL drinking water) for 4 weeks. The high-salt diet provoked an increase in glomerular injuries accompanied with albuminuria and in urinary H2O2 and MCP-1 excretion. Immunohistochemical analysis showed the prominent expression of MCP-1 in the dilated tubular cells, where the NADPH oxidase subunit p47phox was also expressed. The current results suggest that albuminuria caused expression of NADPH oxidase and MCP-1 in the dilated renal tubules, resulting in interstitial inflammation and migration of mononuclear cells in DSS rats, because block- ade of albuminuria by NAC counteracted the p47phox and MCP-1 expression.
    [Show full text]
  • Lloyd Graham, Et Al. V. Olympus Corporation, Et Al. 11-CV-07103
    Case 5:11-cv-07103-JKG Document 50 Filed 01/15/13 Page 1 of 111 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA CHAITANYA KADIYALA and KELLY SHARKEY, on behalf of themselves Case No. 1 1-cv-7 103 individually and all others similarly situated, Plaintiffs, V. OLYMPUS CORPORATION, TSUYOSHI KIKUKAWA, and SHUICHI TAKAYAMA, Defendants. PLAINTIFFS' SECOND AMENDED CLASS ACTION COMPLAINT VIANALE & VIANALE LLP LITE DEPALMA GREENBERG, LLC Kenneth J. Vianale (admitted pro hac vice) Steven Greenfogel 2499 Glades Road, Suite 112 Daniel B. Allanoff Boca Raton, FL 33431 1521 Locust Street, 8th Floor Tel: (561) 392-4750 Philadelphia, PA 19102 Tel: (215) 564-5182 SARRAF GENTILE LLP Ronen Sarraf (admitted pro hac vice) Liaison Counsel for Plaintiffs Joseph Gentile (admitted pro hac vice) 450 Seventh Avenue, Suite 1900 New York, New York 10123 Tel: (212) 868-3610 Co-Lead Counsel for Plaintiffs Case 5:11-cv-07103-JKG Document 50 Filed 01/15/13 Page 2 of 111 TABLE OF CONTENTS I. NATURE OF THE ACTION ......................................................................................... 1 II. BASIS OF THE ALLEGATIONS.................................................................................2 III. JURISDICTION AND VENUE.................................................................................... 5 IV. PARTIES.......................................................................................................................6 A. Plaintiffs .............................................................................................................
    [Show full text]
  • Olympus Scandal and Corporate Governance Reform: Can Japan Find a Middle Ground Between the Board Monitoring Model and Management Model
    UCLA UCLA Pacific Basin Law Journal Title The Olympus Scandal and Corporate Governance Reform: Can Japan Find a Middle Ground between the Board Monitoring Model and Management Model Permalink https://escholarship.org/uc/item/9v5803kw Journal UCLA Pacific Basin Law Journal, 30(1) Author Aronson, Bruce E. Publication Date 2012 DOI 10.5070/P8301022242 Peer reviewed eScholarship.org Powered by the California Digital Library University of California THE OLYMPUS SCANDAL AND CORPORATE GOVERNANCE REFORM: CAN JAPAN FIND A MIDDLE GROUND BETWEEN THE BOARD MONITORING MODEL AND MANAGEMENT MODEL? By Bruce E. Aronson* TABLE OF CONTENTS I. Introduction ................................. 95 II. The Olympus Scandal and Corporate Governance Issues ..................................... 106 A. Background of the Olympus Case ............ 106 B. Monitoring of Management under Japan's Corporate Governance System .............. 115 III. Back to Basics: Revisiting Theoretical and Structural Issues ............................ 120 A. Purpose of Corporate Governance Reform .... 120 B. Monitoring Function of the Board of Directors..... ........................ 125 IV. Practical Issues: Achieving "Truly Effective" Corporate Governance Reform ................. 129 A. Information ............................. 130 1. Internal Sharing of Information .......... 130 2. Public Information Disclosure ............ 132 * Senior Fulbright Research Scholar, Waseda University; Professor of Law, Creighton University School of Law. I thank Mr. Sumitaka Fujita, Professor Yumiko Miwa, and Mr. Naoaki Okabe for acting as a panel of commentators following my presentation on this research at the Meiji Institute for Global Affairs Inaugural Symposium, Tokyo, Japan (Feb. 21, 2012), and participants in presentations at Nagoya University (April 20, 2012), AIMA Japan Hedge Fund Forum 2012, Tokyo Stock Exchange (June 4, 2012), 2012 International Conference on Law & Society, Law & Society Association, Honolulu (June 5, 2012), and Business Research Institute, Tokyo (Aug.
    [Show full text]